PATENT CLAIM ANALYSIS

Application Number: 15900043
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "379000"]

Abstract:
The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Claim (Index 10):
A pharmaceutical composition comprising:\n a) a compound of Formula (I) or pharmaceutically acceptable salt thereof as defined in  claim 6 ; and b) a pharmaceutically acceptable excipient.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 88.0
- Lexical Diversity: 1.72043
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15537805', '15574947', '15813001', '13963822', '14390190']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7354923615573535
- 35 USC 102 Novelty (BERT): 0.584183462499546
- Combined Prediction Score: 0.7203614716515727
- Mean Citation Score: 337.647236
- Max Citation Score: 502.37387
- Similarity Product: 392.9666520496261

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test